The adjuvant treatment revolution for high-risk melanoma patients

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• The last five years have seen significant advancements in adjuvant therapy for resected, high-risk melanoma.
• Previous adjuvant treatments, like interferon, have been largely superseded by newer modalities.
• Two major studies have impacted surgical decision-making regarding lymph node dissection.

Purpose of the Study:

• To review the current landscape of adjuvant treatment for high-risk melanoma.
• To discuss the impact of recent practice-changing studies.
• To provide insights into future directions in melanoma adjuvant therapy.

Main Methods:

• Review of recent practice-changing clinical trials and studies.
• Synthesis of data on immune-checkpoint inhibitors (anti-CTLA-4, anti-PD-1) and targeted therapy (MAPK-directed).
• Analysis of results from large multicenter studies on completion lymph node dissection.

Main Results:

• Immune-checkpoint inhibitors and MAPK-targeted therapies have revolutionized melanoma adjuvant treatment.
• Completion lymph node dissection does not improve overall survival in patients with a positive sentinel node biopsy.
• These advancements represent a paradigm shift from the previous 20-year era of adjuvant interferon therapy.

Conclusions:

• Current adjuvant treatment for high-risk melanoma is highly effective, offering improved outcomes.
• The role of completion lymph node dissection is now limited, based on survival data.
• Future perspectives in melanoma adjuvant therapy are promising, building on recent breakthroughs.